Aptose Biosciences (APS) AI Stock Analysis

• Market Cap: C$6.09M
• Dividend Yield: N/A
• Average Volume (3M): 3.35K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.98
• Revenue Growth: N/A
• EPS Growth: 90.81%
• Country: CA
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.19
• Shares Outstanding: 2,552,429
• 10 Day Avg. Volume: 4,664
• 30 Day Avg. Volume: 3,346
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -5.65
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$2.50 ▲(15.74% Upside)
• Action: Reiterated Date: 04/09/26
• Date: Action: Reiterated 04/09/26

Overall score is held down primarily by weak financial performance—no revenue, ongoing losses/cash burn, and a stressed balance sheet with negative equity and rising debt. Technical indicators are comparatively better (price above major moving averages with positive MACD), providing partial support, while valuation remains unattractive due to negative earnings and no dividend.

Positive Factors

Focused Pipeline

Aptose’s concentrated pipeline in targeted small-molecule kinase inhibitors (tuspetinib, luxeptinib) establishes a clear strategic focus on hematologic malignancies such as AML. This specialization builds durable scientific expertise and regulatory clarity that can sustain value creation through clinical milestones and partnerships over months.

Negative Factors

No Revenue

Absence of product revenue means the company is entirely dependent on external financing and partnerships to fund operations. Over a multi-month horizon this sustains capital markets and partner dependency risk, limiting internal cash generation and leaving strategic options constrained if financing terms deteriorate.

Aptose Biosciences Business Overview & Revenue Model

Company Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/...

Read more

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/...

How the Company Makes Money

null...

Aptose Biosciences Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-425.32K	0.00	-474.55K	-507.08K	-616.53K
EBITDA	-24.73M	-26.23M	-52.27M	-42.48M	-65.30M
Net Income	-25.91M	-25.43M	-51.21M	-41.82M	-65.35M
Balance Sheet
Total Assets	9.99M	10.13M	12.99M	51.03M	82.53M
Cash, Cash Equivalents and Short-Term Investments	4.09M	6.15M	9.25M	46.96M	79.13M
Total Debt	28.01M	10.64M	1.01M	1.30M	574.00K
Total Liabilities	37.11M	14.67M	15.89M	13.29M	8.29M
Stockholders Equity	-27.12M	-4.54M	-2.90M	37.74M	74.24M
Cash Flow
Free Cash Flow	-22.37M	-35.98M	-44.62M	-32.35M	-43.52M
Operating Cash Flow	-22.37M	-35.98M	-44.59M	-32.32M	-43.30M
Investing Cash Flow	0.00	18.00K	9.96M	30.07M	-35.21M
Financing Cash Flow	19.72M	33.41M	6.91M	116.00K	226.00K

Aptose Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APS, the sentiment is Positive. The current price of 2.16 is below the 20-day moving average (MA) of 2.28, below the 50-day MA of 2.24, and above the 200-day MA of 1.99, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 64.03 is Neutral, neither overbought nor oversold. The STOCH value of 90.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:APS.

Aptose Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BETR	52 Neutral	C$9.87M	-6.03	19.14%	―	―	62.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APS	48 Neutral	C$6.09M	-0.13	123.88%	―	―	90.81%
XRTX	42 Neutral	C$5.07M	-0.98	-111.11%	―	―	-1939.32%
KNE	41 Neutral	C$5.46M	-3.10	―	―	―	―
BIOV	―	C$1.75M	-1.60	―	―	―	25.09%

Aptose Biosciences Corporate Events